If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

A UPMC pulmonologist discusses RSV, including what the symptoms are, who is most at risk and how effective the vaccine is.

Derived from the Latin adjuvare (to help or aid), adjuvants enhance antigen-specific vaccine immunogenicity. Added only when ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID ...

Moderna has delayed its break-even goal by two years, pushing it to 2028, due to slower regulatory processes for key products ...

The vaccine maker last month projected sales of $3 billion and $3.5 billion for this year, which will be its lowest annual ...

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

CORRECTION: An earlier version of this story misstated the number of RSV vaccines approved ... which was the first time the COVID-19 vaccine was managed by commercial supply chains instead of ...